Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
CASE 13 Surgery Presentation
CASE PRESENTATION <ul><li>A resection was performed on for cure in a 51 year old man who was found to have Stage II colon ...
DIFFERENTIAL DIAGNOSIS <ul><li>Colorectal cancer </li></ul><ul><li>Liver cancer </li></ul><ul><li>Prostate cancer </li></u...
DIFFERENTIAL DIAGNOSIS (CONT.) <ul><li>Diverticulitis </li></ul><ul><li>Peptic Ulcer Disease </li></ul><ul><li>Bronchitis ...
ADDITIONAL TESTS <ul><li>Detailed H&P </li></ul><ul><li>Abdominal CT  </li></ul><ul><li>PET scan </li></ul><ul><li>CBC to ...
POSSIBLE SCENARIOS Scenario Management Large extraluminal mass in the abdomen CT with oral and IV contrast to determine if...
PROGNOSIS <ul><li>What would we tell the patient about his prognosis in the case of a solitary 2 cm mass found in the righ...
PROGNOSIS (CONT) <ul><li>What would we tell the patient about his prognosis in the case of a solitary 2 cm mass found in t...
Upcoming SlideShare
Loading in …5
×

Second Year Surgery Case Presentation

7,377 views

Published on

Published in: Health & Medicine
  • Be the first to comment

Second Year Surgery Case Presentation

  1. 1. CASE 13 Surgery Presentation
  2. 2. CASE PRESENTATION <ul><li>A resection was performed on for cure in a 51 year old man who was found to have Stage II colon cancer. </li></ul><ul><li>His initial CEA was low </li></ul><ul><li>No recurrent masses were found in a repeat colonoscopy at one year and two years. </li></ul><ul><li>CEA at one year was still low; however, at two years is found to be elevated several fold. </li></ul>
  3. 3. DIFFERENTIAL DIAGNOSIS <ul><li>Colorectal cancer </li></ul><ul><li>Liver cancer </li></ul><ul><li>Prostate cancer </li></ul><ul><li>Stomach cancer </li></ul><ul><li>Pancreatic cancer </li></ul><ul><li>Lung cancer </li></ul><ul><li>Breast cancer </li></ul>Citation: Schwartz’s Principles of Surgery, 8 th edition, 2005
  4. 4. DIFFERENTIAL DIAGNOSIS (CONT.) <ul><li>Diverticulitis </li></ul><ul><li>Peptic Ulcer Disease </li></ul><ul><li>Bronchitis </li></ul><ul><li>Liver Abscess </li></ul><ul><li>Pancreatitis </li></ul><ul><li>Cirrhosis </li></ul>Citation: Schwartz’s Principles of Surgery, 8 th edition, 2005
  5. 5. ADDITIONAL TESTS <ul><li>Detailed H&P </li></ul><ul><li>Abdominal CT </li></ul><ul><li>PET scan </li></ul><ul><li>CBC to evaluate infection </li></ul><ul><li>CMP to evaluate liver enzymes </li></ul><ul><li>Lipase and amylase to evaluate pancreatic function </li></ul><ul><li>PSA levels </li></ul><ul><li>Rectal ultrasound </li></ul>
  6. 6. POSSIBLE SCENARIOS Scenario Management Large extraluminal mass in the abdomen CT with oral and IV contrast to determine if fluid-filled. If abscess, FNA and percutaneous CT-guided catheter drainage If not, biopsy. No mass is found Further investigate non-malignant causes of CEA increase Solitary 2 cm mass is found in the right lobe of the liver Surgical resection Widely disseminated diffuse mass effect is seen throughout the abdomen and pelvis First line therapy: 5-fluorouracil and leucovorin. Second line: irinotecan. Surgery for palliative care in the case of obstructions and adhesions, or diagnostic/staging purposes.
  7. 7. PROGNOSIS <ul><li>What would we tell the patient about his prognosis in the case of a solitary 2 cm mass found in the right lobe of the liver? </li></ul><ul><li>Surgery is limited to unilobar disease without extrahepatic disease. </li></ul><ul><ul><li>20 – 30% 5-year survival </li></ul></ul><ul><ul><li>< 6% operative mortality </li></ul></ul><ul><li>Resection of liver metastases may be beneficial in selected patients with colorectal or gastric carcinoma </li></ul>(J Clin Oncol 1997 Mar;15;938, Am J Gastroenterol 1997 Mar;92;490 in J Watch 1997 Apr 15;17(8);65)
  8. 8. PROGNOSIS (CONT) <ul><li>What would we tell the patient about his prognosis in the case of a solitary 2 cm mass found in the right lobe of the liver? </li></ul><ul><li>If unresectable, treated with regional chemotherapy (5-florouracil) through the hepatic artery. </li></ul><ul><ul><li>(Surgery: Scientific Principles and Practice 3 rd edition, ph 1128) </li></ul></ul><ul><li>If no treatment at all, mean survival time is 12 months. </li></ul><ul><ul><li>( Ugeskr Laeger. 1989 Apr 24;151(17):1045-8. PMID: 2660370) </li></ul></ul>

×